Comparable performance of the kansas city cardiomyopathy questionnaire in patients with heart failure with preserved and reduced ejection fraction

Circulation: Heart Failure

Volumn 6, Issue 6, 2013, Pages 1139-1146

  Joseph, Susan M ^a   Novak, Eric ^a   Arnold, Suzanne V ^b   Jones, Philip G ^b   Khattak, Himad ^a   Platts, Anne E ^a   Davila Roman, Victor G ^a   Mann, Douglas L ^a   Spertus, John A ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Health status; Heart failure diastolic; Quality of life

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DABIGATRAN ETEXILATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; NITRATE; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CRITERION RELATED VALIDITY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEALTH STATUS; HEART FAILURE; HEART FAILURE PRESERVED EJECTION FRACTION; HEART FAILURE REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; INFANT; INTERNAL CONSISTENCY; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; PREDICTIVE VALIDITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCHOOL CHILD; SYMPTOM; VERY ELDERLY; YOUNG ADULT; COMPARATIVE STUDY; DIASTOLIC HEART FAILURE; DISEASE COURSE; HEART STROKE VOLUME; INCIDENCE; PATHOPHYSIOLOGY; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

HEALTH STATUS; HEART FAILURE, DIASTOLIC; QUALITY OF LIFE;

DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; UNITED STATES;

EID: 84892656686     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000359     Document Type: Article

References (45)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
2. Hogg K, McMurray J. The treatment of heart failure with preserved ejection fraction ("diastolic heart failure"). Heart Fail Rev. 2006;11:141-146.
3. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317-327.
4. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:163-169.
5. Speight J, Barendse SM. FDA guidance on patient reported outcomes. Bmj. 2010;340:c2921.
6. Spertus JA. Evolving applications for patient-centered health status measures. Circulation. 2008;118:2103-2110.
7. Sullivan MD, Levy WC, Russo JE, Crane B, Spertus JA. Summary health status measures in advanced heart failure: relationship to clinical variables and outcome. J Card Fail. 2007;13:560-568.
8. Luther SA, McCullough PA, Havranek EP, Rumsfeld JS, Jones PG, Heidenreich PA, Peterson ED, Rathore SS, Krumholz HM, Weintraub WS, Spertus JA, Masoudi FA; Cardiovascular Outcomes Research Consortium. The relationship between B-type natriuretic peptide and health status in patients with heart failure. J Card Fail. 2005;11:414-421.
9. Chan PS, Soto G, Jones PG, Nallamothu BK, Zhang Z, Weintraub WS, Spertus JA. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation. 2009;119:398-407.
10. Spertus JA, Jones PG, Kim J, Globe D. Validity, reliability, and responsiveness of the Kansas City Cardiomyopathy Questionnaire in anemic heart failure patients. Qual Life Res. 2008;17:291-298.
11. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245-1255.
12. Myers J, Zaheer N, Quaglietti S, Madhavan R, Froelicher V, Heidenreich P. Association of functional and health status measures in heart failure. J Card Fail. 2006;12:439-445.
13. Parissis JT, Nikolaou M, Farmakis D, Paraskevaidis IA, Bistola V, Venetsanou K, Katsaras D, Filippatos G, Kremastinos DT. Selfassessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure. Eur J Heart Fail. 2009;11:163-169.
14. Soto GE, Jones P, Weintraub WS, Krumholz HM, Spertus JA. Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation. 2004;110:546-551.
15. Faller H, Steinbu chel T, Schowalter M, Spertus JA, Sto rk S, Angermann CE. The Kansas City Cardiomyopathy Questionnaire (KCCQ)-a new disease-specific quality of life measure for patients with chronic heart failure. Psychother Psychosom Med Psychol. 2005;55:200-208.
16. Flynn KE, Lin L, Moe GW, Howlett JG, Fine LJ, Spertus JA, McConnell TR, Pin a IL, Weinfurt KP. Relationships between changes in patientreported health status and functional capacity in outpatients with heart failure. Am Heart J. 2012;163:88-94.e3.
17. Flynn KE, Pin a IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG, Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, O?Connor CM, Weinfurt KP; HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. Jama. 2009;301:1451-1459.
18. Heidenreich PA, Spertus JA, Jones PG, Weintraub WS, Rumsfeld JS, Rathore SS, Peterson ED, Masoudi FA, Krumholz HM, Havranek EP, Conard MW, Williams RE; Cardiovascular Outcomes Research Consortium. Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol. 2006;47:752-756.
19. Kosiborod M, Soto GE, Jones PG, Krumholz HM, Weintraub WS, Deedwania P, Spertus JA. Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation. 2007;115:1975-1981.
20. Arnold SV, Spertus JA, Jones PG, Xiao L, Cohen DJ. The impact of dyspnea on health-related quality of life in patients with coronary artery disease: results from the PREMIER registry. Am Heart J. 2009;157:1042-9.e1.
21. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN; Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:e1-194.
22. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123:2006-13; discussion 2014.
23. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-679.
24. Zile MR. Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol. 2003;41:1519-1522.
25. Burkhoff D, Maurer MS, Packer M. Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? Circulation. 2003;107:656-658.
26. Bland JM, Altman DG. Cronbach?s alpha. Bmj. 1997;314:572.
27. Guller U, DeLong ER. Interpreting statistics in medical literature: a vade mecum for surgeons. J Am Coll Surg. 2004;198:441-458.
28. Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol. 2001;38:1277-1282.
29. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982-1990.
30. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. Jama. 2006;296:2209-2216.
31. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47:320-332.
32. Hoekstra T, Jaarsma T, van Veldhuisen DJ, Hillege HL, Sanderman R, Lesman-Leegte I. Quality of life and survival in patients with heart failure. Eur J Heart Fail. 2013;15:94-102.
33. Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O?Meara E, Shaburishvili T, Pitt B, Pfeffer MA. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011;162:966-972.e10.
34. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5:720-726.
35. Dracup K, Walden JA, Stevenson LW, Brecht ML. Quality of life in patients with advanced heart failure. J Heart Lung Transplant. 1992;11(2 Pt 1):273-279.
36. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant. 2001;20:1016-1024.
37. Stevenson LW. Counting performance with therapies for heart failure: aiming for quality or quantity? Circulation. 2010;122:561-566.
38. Parthasarathy HK, Pieske B, Weisskopf M, Andrews CD, Brunel P, Struthers AD, MacDonald TM. A randomized, double-blind, placebocontrolled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. Eur J Heart Fail. 2009;11:980-989.
39. Daniel KR, Wells G, Stewart K, Moore B, Kitzman DW. Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail. 2009;15:68-74.
40. Arnold SV, Spertus JA, Lei Y, Allen KB, Chhatriwalla AK, Leon MB, Smith CR, Reynolds MR, Webb JG, Svensson LG, Cohen DJ. Use of the Kansas City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic stenosis. Circ Heart Fail. 2013;6:61-67.
41. Somaratne JB, Berry C, McMurray JJ, Poppe KK, Doughty RN, Whalley GA. The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur J Heart Fail. 2009;11:855-862.
42. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J.. 2012;33:1750-1757.
43. Lewis EF, Lamas GA, O?Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B, McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9:83-91.
44. O?Meara E, Lewis E, Granger C, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Ostergren J, Carlsson J, Olofsson B, McMurray J, Yusuf S, Swedberg K, Pfeffer MA. Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2005;7:650-656.
45. Hoekstra T, Lesman-Leegte I, van Veldhuisen DJ, Sanderman R, Jaarsma T. Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail. 2011;13:1013-1018.